Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GC012F in Relapsed or Refractory AL Amyloidosis
NCT07250269Phase 1Recruiting
- Sponsor
- Gracell Biotechnologies
- Start
- Oct 2025
- Primary completion
- Nov 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GC012 in amyloid light chain amyloidosis, sponsored by Gracell Biotechnologies. Primary endpoints: Treatment-emergent Adverse Events at 2 years and Dose-limiting Toxicities at 2 years. Started Oct 2025; status: recruiting.
02
Drugs
GC012
03
Conditions
amyloid light chain amyloidosis
Beyond the preview
Go deeper on NCT07250269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07250269.